Abstract
In this issue of Blood, Wang et al report their phase 1 trial of CT103, a fully human 4-1BB zeta chimeric antigen receptor (CAR) targeting the B-cell ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
